Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06651580 2026-03-04

Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

Recruiting

1,600 enrolled

Gastrointestinal

Pancreatic Neoplasms, Pancreatitis, Pancreatitis, Chronic

NCT04975516 2026-03-03

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer

Phase 2 Terminated

3 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06998940 2026-02-20

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Phase 3 Recruiting

94 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT07214298 2026-02-06

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

35 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06958328 2026-02-02

LAP100

Phase 3 Recruiting

356 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06381154 2026-01-30

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06073431 2026-01-09

LOTUS

Recruiting

800 enrolled

GastrointestinalThoracic

Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07326150 2026-01-08

Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer

Active not recruiting

70 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07226856 2025-12-22

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Phase 2 Recruiting

43 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06744595 2025-12-12

Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic Cancer

Phase NA Enrolling by invitation

40 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06807437 2025-12-05

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

Phase 3 Recruiting

274 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02595931 2025-11-17

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Active not recruiting

66 enrolled

GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT06423326 2025-07-30

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Phase 2 Recruiting

36 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT07089940 2025-07-29

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Phase EARLY_PHASE1 Not yet recruiting

12 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04616534 2025-05-22

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Phase 1 Active not recruiting

14 enrolled

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06454383 2025-04-10

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Phase 1 Recruiting

19 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01585805 2025-03-11

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

88 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04514497 2025-03-06

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Phase 1 Active not recruiting

28 enrolled

EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05523154 2025-02-18

"Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures

Phase NA Terminated

8 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT06206876 2025-01-17

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT04067960 2024-08-14

Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer

Phase EARLY_PHASE1 Completed

197 enrolled

CNSGastrointestinalGenitourinaryGynecologic

Brain Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

NCT06398587 2024-07-19

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05238831 2024-01-23